Kytopen Corp, a leader in non-viral, continuous flow cellular engineering, and TQ Therapeutics (TQx), a pioneer in modular, target-cell–specific gene modification, has announced a new partnership granting TQx access to Kytopen’s Flowfect technology through the company’s Technology Access Program (TAP). The collaboration marks another milestone in Kytopen’s growing footprint across Europe.

 

TQ Therapeutics will leverage Flowfect as a core module of its CELLfinity platform, integrating it into its proprietary EXiVO approach—an extracorporeal gene-therapy process that precisely modifies T cells directly from patients’ unprocessed whole blood using FABfinity cell-selection technology. 

 

The partnership aims to combine TQx’s in vivo therapeutic expertise with Kytopen’s continuous flow transfection technology, capable of rapidly engineering hundreds of billions of healthy cells in minutes using mechanical, electrical, and chemical forces. Together, the companies hope to drive a new generation of autologous mRNA T-cell therapies across multiple disease areas.

 

Through TAP, TQ Therapeutics will receive proof-of-concept and process-development support, on-site installation of the Flowfect Tx system, and guidance from Kytopen’s Field Applications Team. The collaboration also provides TQx access to the Flowfect Discover 96-well optimization platform, streamlining development from early feasibility testing to clinical and commercial manufacturing.

 

“Our partnership with TQ Therapeutics represents a shared vision to transform the landscape of engineered cell therapies,” said Kevin Gutshall, Chief Commercial Officer at Kytopen. “By integrating Flowfect technology with TQx's groundbreaking in vivo CELLfinity platform, we are not just advancing technology—we are opening the door to entirely new therapeutic possibilities that have the potential to redefine patient care.”

 

Christian Stemberger, Chief Scientific Officer at TQ Therapeutics, added, “We are delighted to partner with Kytopen and to integrate the Flowfect technology into our TQx platform. The seamless compatibility of the Flowfect Tx system with our extracorporeal in vivo cell therapy approach enhances our ability to efficiently engineer cells with high precision and safety. 

 

"Access to the Flowfect Discover platform further accelerates our development pathway—from rapid optimization through to clinical readiness—strengthening our mission to deliver transformative therapies to patients.”